Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating endometriosis

Abstract

The invention relates to the technical field of traditional Chinese medicine, in particular to application of a traditional Chinese medicine composition in preparation of medicine for preventing and treating endometriosis, and the traditional Chinese medicine composition comprises spina gleditsiae, polygonum cuspidatum, dandelion, sargentgloryvine stem, codonopsis pilosula, chinaroot greenbrier, radix paeoniae rubra, salvia miltiorrhiza, lindera aggregata and corydalis tuber. Experimental results show that the number of writhing times of mice fed with the traditional Chinese medicine composition is remarkably reduced, the ectopic endometrial volume is remarkably reduced, and serum PGE2 and PGF2 alpha secretion is remarkably reduced, so that the traditional Chinese medicine composition has a good treatment effect on endometriosis.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to application of a traditional Chinese medicine composition in preparing medicines for preventing and treating endometriosis. Background Art

[0002] Endometriosis refers to the appearance of endometrial tissue (glands and stroma) with growth, implantation and infiltration activity in other parts of the uterus. It is a common chronic endometrial disease. The incidence of this disease accounts for 10% to 15% of women of childbearing age, and it is increasing every year. Although it is a benign disease, its recurrence rate is high and it is difficult to cure, which seriously affects the patient's physical and mental health and quality of life. Some patients may even experience a series of mental symptoms, such as depression, anxiety, etc., which have a negative impact on their daily life, sexual function and interpersonal relationships.

[0003] At present, the etiology and pathological mechanism of endometriosis are not fully understood.

[0004] All treatments for endometriosis are suppressive rather than curative. Long-term hormone therapy for this disease has many side effects, resulting in reduced patient compliance, while surgical treatment is more damaging to patients and has a high recurrence rate. Traditional Chinese medicine is an empirical medicine, and some patients with endometriosis will choose Chinese medicine to improve their symptoms and relieve anxiety. Compared with hormone and surgical treatments, Chinese medicine is guided by a holistic concept and can effectively relieve persistent lesions of uterine endometriosis. It has a quick effect, a low recurrence rate, and a stable long-term efficacy. Summary of the invention

[0005] In view of this, the problem to be solved by the present invention is to provide an application of a Chinese medicine composition in the preparation of a medicine for preventing and treating endometriosis.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides the use of a traditional Chinese medicine composition in preparing a medicine for preventing and treating endometriosis;

[0008] The Chinese medicine composition comprises the following raw materials in parts by mass, or is made from the following raw materials in parts by mass:

[0009] 8-15 parts of Gleditsia sinensis thorns, 6-10 parts of Polygonum cuspidatum, 8-12 parts of Taraxacum herba, 8-12 parts of Sargentodoxae, 8-15 parts of Codonopsis pilosula, 8-15 parts of Smilax china, 6-10 parts of Paeonia lactiflora, 8-15 parts of Salvia miltiorrhiza, 6-10 parts of Linderae umbellatae and 8-12 parts of Corydalis yanhusuo.

[0010] In some specific embodiments, the Chinese medicine composition includes: 12 parts of Gleditsia sinensis, 8 parts of Polygonum cuspidatum, 9.6 parts of Taraxacum mongolicum, 9.6 parts of Sargentodoxa chinensis, 12 parts of Codonopsis pilosula, 12 parts of Smilax china, 8 parts of Paeonia lactiflora, 12 parts of Salvia miltiorrhiza, 8 parts of Linderae scutellariae and 9.6 parts of Corydalis yanhusuo.

[0011] In some specific embodiments, the Chinese medicine composition comprises: 8 parts of Gleditsia sinensis, 6 parts of Polygonum cuspidatum, 8 parts of Taraxacum mongolicum, 8 parts of Sargentodoxa chinensis, 8 parts of Codonopsis pilosula, 8 parts of Smilax china, 6 parts of Paeonia lactiflora, 8 parts of Salvia miltiorrhiza, 6 parts of Linderae umbellatae and 8 parts of Corydalis yanhusuo;

[0012] In some specific embodiments, the Chinese medicine composition includes: 15 parts of Gleditsia sinensis, 10 parts of Polygonum cuspidatum, 12 parts of Taraxacum herb, 12 parts of Sargentodoxa chinensis, 15 parts of Codonopsis pilosula, 15 parts of Smilax china, 10 parts of Paeonia lactiflora, 15 parts of Salvia miltiorrhiza, 10 parts of Linderae umbellatae and 12 parts of Corydalis yanhusuo.

[0013] In the present invention, the preparation method of the Chinese medicine composition comprises the following steps:

[0014] Add 60% to 80% ethanol to Corydalis yanhusuo and Polygonum cuspidatum in 6-10 times amount, reflux extract 1-3 times, each time for 0.5 to 2.5 hours, filter, combine the filtrate, and obtain the alcohol extract;

[0015] Add 10-15 times the amount of water to Gleditsia sinensis, dandelion, Sarsaparilla dahurica, Codonopsis pilosula, Smilax china, Paeonia lactiflora, Salvia miltiorrhiza, and Linderae striata, and boil for 1-4 times, each time for 1-3 hours, filter, combine the filtrate, concentrate under reduced pressure, add ethanol until the alcohol content reaches 60%, let stand for 24-36 hours, and collect the alcohol precipitation supernatant;

[0016] The alcohol precipitation supernatant and the alcohol extract are combined, concentrated under reduced pressure to obtain an extract, 1-3 times the weight of water of the extract is added to mix well, and allowed to stand for 24-36 hours; the supernatant is taken, dried, and crushed.

[0017] In the present invention, the prevention and treatment include: reducing the volume of ectopic endometrium, reducing the level of prostaglandins and / or reducing the number of painful twisting.

[0018] In some specific embodiments, the prostaglandin is a prostaglandin in serum, and the prostaglandin includes PGE2 and / or PGF2α.

[0019] In the present invention, the effective dosage of the Chinese medicine composition for treating endometriosis is 201.6 g to 403.2 g of the raw medicine per day.

[0020] The present invention also provides a drug for preventing and treating endometriosis, comprising the following raw materials in parts by weight, or made from the following raw materials in parts by weight:

[0021] 8-15 parts of Gleditsia sinensis spines, 6-10 parts of Polygonum cuspidatum, 8-12 parts of Taraxacum herba, 8-12 parts of Sargentodoxae, 8-15 parts of Codonopsis pilosula, 8-15 parts of Smilax china, 6-10 parts of Paeonia lactiflora, 8-15 parts of Salvia miltiorrhiza, 6-10 parts of Linderae umbellatae, and 8-12 parts of Corydalis yanhusuo.

[0022] After the Chinese medicine composition of the present invention is prepared according to the above proportions and preparation methods, conventional pharmaceutical excipients in Chinese medicine preparations can be added and conventional pharmaceutical methods in pharmacy can be used to prepare the desired Chinese medicine preparations, including but not limited to granules, capsules, pills, tablets and suppositories.

[0023] The present invention provides an application of a Chinese medicine composition in the preparation of a medicine for preventing and treating endometriosis, wherein the Chinese medicine composition comprises Gleditsia sinensis, Polygonum cuspidatum, Taraxacum officinale, Sargentodoxae, Codonopsis pilosula, Smilax china, Paeonia lactiflora, Salvia miltiorrhiza, Linderae umbellatae and Corydalis yanhusuo. Experimental results show that the number of writhing times of mice given the Chinese medicine composition is significantly reduced, the volume of ectopic endometrium is significantly reduced, and the secretion of serum PGE2 and PGF2α is significantly reduced, indicating that the Chinese medicine composition has a good therapeutic effect on endometriosis. DETAILED DESCRIPTION

[0024] The present invention provides the use of a Chinese medicine composition in the preparation of a drug for preventing and treating endometriosis. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0025] As mentioned above, the present invention aims to provide a use of a Chinese medicine composition in the preparation of a drug for preventing and treating endometriosis;

[0026] The Chinese medicine composition comprises the following raw materials in parts by mass, or is made from the following raw materials in parts by mass:

[0027] 8-15 parts of Gleditsia sinensis thorns, 6-10 parts of Polygonum cuspidatum, 8-12 parts of Taraxacum herba, 8-12 parts of Sargentodoxae, 8-15 parts of Codonopsis pilosula, 8-15 parts of Smilax china, 6-10 parts of Paeonia lactiflora, 8-15 parts of Salvia miltiorrhiza, 6-10 parts of Linderae umbellatae and 8-12 parts of Corydalis yanhusuo.

[0028] In the present invention, the preparation method of the Chinese medicine composition comprises

[0029] Add 60% to 80% ethanol to Corydalis yanhusuo and Polygonum cuspidatum in 6-10 times amount, reflux extract 1-3 times, each time for 0.5 to 2.5 hours, filter, combine the filtrate, and obtain the alcohol extract;

[0030] Add 10-15 times the amount of water to Gleditsia sinensis, dandelion, Sarsaparilla dahurica, Codonopsis pilosula, Smilax china, Paeonia lactiflora, Salvia miltiorrhiza, and Linderae striata, and boil for 1-4 times, each time for 1-3 hours, filter, combine the filtrate, concentrate under reduced pressure, add ethanol until the alcohol content reaches 60%, let stand for 24-36 hours, and collect the alcohol precipitation supernatant;

[0031] The alcohol precipitation supernatant and the alcohol extract are combined, concentrated under reduced pressure to obtain an extract, 1-3 times the weight of water of the extract is added to mix well, and allowed to stand for 24-36 hours; the supernatant is dried and crushed, conventional pharmaceutical excipients are added, and the desired Chinese medicine dosage form is prepared by conventional methods in pharmacy.

[0032] In some specific embodiments, the preparation method of the Chinese medicine composition comprises:

[0033] Add 10 times the amount of 60% ethanol to Corydalis yanhusuo and Polygonum cuspidatum, reflux and extract for 3 times, each time for 1.5 hours, filter, combine the filtrates, and obtain the alcohol extract;

[0034] Gleditsia sinensis, dandelion, Sargentodoxae, Codonopsis pilosula, Smilax china, Paeonia lactiflora, Salvia miltiorrhiza, and Linderae umbellatae are added with 10 times of water, boiled for 3 times, each time for 1.5 hours, filtered, combined with the filtrate, concentrated under reduced pressure to an extract with a relative density of 1.08-1.12 (60°C-70°C), added with ethanol to make the alcohol content of the medicinal solution reach 60%, and allowed to stand for 24 to 36 hours. The alcohol precipitation supernatant is taken, combined with the alcohol extract, concentrated under reduced pressure to an extract with a relative density of 1.04-1.06 (60°C-70°C), water of 1 times the weight of the extract is added and mixed, allowed to stand for 24 to 36 hours, the supernatant is taken, concentrated under reduced pressure to an extract with a relative density of 1.12-1.18 (60°C-70°C), spray dried, crushed to obtain a dry paste powder, added with appropriate amounts of dextrin and stevioside, dry granulated, and made into 1000g granules.

[0035] The following experiments, if no specific conditions are specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The APIs or excipients, reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially. Unless otherwise specified, all percentages, ratios, proportions or parts are by weight.

[0036] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention.

[0037] The present invention will be further described below in conjunction with embodiments:

[0038] Example 1 Preparation of Chinese medicine composition

[0039] The Chinese medicine composition granules are prepared from the following raw materials in parts by weight: 15 parts of Gleditsia sinensis thorns, 10 parts of Polygonum cuspidatum, 12 parts of Taraxacum herba, 12 parts of Sargentodoxae cyrtonema, 15 parts of Codonopsis pilosula, 15 parts of Smilax china, 10 parts of Paeonia lactiflora, 15 parts of Salvia miltiorrhiza, 10 parts of Linderae umbellatae and 12 parts of Corydalis yanhusuo.

[0040] The above ten medicinal materials were processed by ethanol reflux extraction and water extraction. Among them, Polygonum cuspidatum and Corydalis yanhusuo were refluxed and extracted 3 times with 10 times the amount of 60% ethanol, each time for 1.5 hours, filtered, and the filtrate was combined to obtain an alcohol extract for standby use; the remaining eight medicinal materials were decocted 3 times with 10 times the amount of water, each time for 1.5 hours, filtered, and the filtrate was combined, and concentrated under reduced pressure to an extract with a relative density of 1.08-1.12 (60°C-70°C), and ethanol was added to make the alcohol content of the medicinal solution reach 60%, and it was allowed to stand for 2 hours. After 4 to 36 hours, the supernatant of the alcohol precipitation is taken, combined with the alcohol extract, concentrated under reduced pressure to an extract with a relative density of 1.04-1.06 (60°C-70°C), 1 times the weight of water of the extract is added and mixed, and the mixture is allowed to stand for 24 to 36 hours. The supernatant is taken, concentrated under reduced pressure to an extract with a relative density of 1.12-1.18 (60°C-70°C), spray-dried, and pulverized to obtain a dry paste powder, and an appropriate amount of dextrin and stevioside are added, and dry granulation is performed to prepare 1000g granules.

[0041] Experimental Example 2 Therapeutic effect of Chinese medicine composition on endometriosis in rats

[0042] 1. Experimental Materials

[0043] 1.1 Animals

[0044] Fifty SPF-grade SD rats, healthy non-pregnant females, weighing 200-220 g, were purchased from Hangzhou Medical College, production license number: SCXK (Zhejiang) 2019-0002.

[0045] 1.2 Drugs

[0046] The Chinese medicine composition prepared in Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.

[0047] 1.3 Instruments and reagents

[0048] Refrigerator (Haier Company, model: BCD-51OWDEM); electronic balance (Mettler Toledo, model: ME55 / 02); purified water instrument (Millipore, Germany, model: Milli-QPlus); animal weight scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: ACX-SC-DA); multifunctional enzyme microplate reader (Perkin Elmer, model: Inspire); PGE2, PGF2α ELISA detection kit (Nanjing Chuanbo Biotechnology Co., Ltd.); sodium pentobarbital (Sigma, cat. no. 57-33-0); sodium chloride injection (Shaanxi Shengao Animal Pharmaceutical Co., Ltd.)

[0049] 2. Dosage design

[0050] The clinical daily dosage of the Chinese medicine composition is 201.6 g of crude drug / day. According to the body surface area conversion method, the equivalent dose for rats is 201.6 g of crude drug / 60kg*6.2=20.83 g of crude drug / kg. This dose is set as the medium-dose group, the low-dose group is 10.42 g of crude drug / kg, and the high-dose group is 41.66 g of crude drug / kg.

[0051] 3. Experimental Methods

[0052] After 1 week of adaptive feeding, the rats were randomly divided into a normal group, a modeling group, and a high-, medium-, and low-dose group of the Chinese medicine composition, with 10 rats in each group. The modeling group and the drug-administered group were anesthetized by intraperitoneal injection of 2.5% sodium pentobarbital solution, fixed, skin prepared, and disinfected. The abdominal cavity was opened in the middle of the lower abdomen, the uterus was separated, part of the tissue of the right uterine horn was cut, and the endometrium was peeled off. Two fragments of 5 mm × 5 mm were taken with a biopsy punch and transplanted to the mesenteric artery as far away from the incision as possible. Gentamycin was used to flush the abdominal cavity, the abdomen was closed layer by layer, and the incision was sutured. Within 3 days after surgery, 0.1 mL of gentamicin was injected intraperitoneally into the rats to prevent infection. After 4 weeks of modeling, the rat grafts were observed by laparotomy to show oval or round cystic nodules with a height of ≥2 mm, and a large number of blood vessels were formed on the surface, which were closely adhered to the surrounding tissues, indicating that the modeling was successful. A total of 50 rats were successfully modeled. Another 10 rats were taken as the sham operation group, and only the uterine tissue was cut open by laparotomy and then sutured. Drug administration began 4 weeks after modeling. Rats in the sham operation group and the model group were gavaged with an equal volume of 0.9% sodium chloride solution once a day for 28 consecutive days.

[0053] 4. Detection indicators

[0054] 4.1 Detection of ectopic endometrial lesion volume in EMS rats

[0055] 24 hours after the last administration, the rats were killed, the abdominal cavity was opened, and the volume of ectopic endometrial lesions in each group of rats was measured and calculated using a vernier caliper.

[0056] 4.2 ELISA method for detecting the levels of PGE2 and PGF2α in rat serum

[0057] After the rats were killed, blood was collected from the abdominal aorta, placed in a 4°C refrigerator for 3 h, and then centrifuged at 3000 r / min for 15 min (centrifugal radius was 12.5 cm). The supernatant was taken and the levels of PGE2 and PGF2α were detected using ELISA kits.

[0058] 5. Experimental results

[0059] The results of the ectopic endometrium volume of rats after modeling are shown in Table 1. Compared with the normal group, the ectopic endometrium volume of rats in the model group was significantly increased (P < 0.001); compared with the model group, the ectopic endometrium volume of rats in the medium and high dose groups of the Chinese medicine composition was significantly reduced (P < 0.01, P < 0.001).

[0060] The results of serum ELISA test are shown in Table 2. Compared with the normal group, the expression of serum PGE2 and PGF2α in the model group rats was significantly increased (P < 0.01, P < 0.001). Compared with the model group, the PGE2 level in the high-dose group of the Chinese medicine composition was significantly decreased (P < 0.01), and the PGF2α levels in the high- and medium-dose groups of the Chinese medicine composition were significantly decreased (P < 0.01, P < 0.001).

[0061] Table 1 The volume of ectopic endometrium in each group of rats ( n=10)

[0062]

[0063] Note: Compared with the model group, **P<0.01, ***P<0.001.

[0064] Table 2 Serum PGE2 and PGF2α levels in rats with endometriosis in each group ( n=10)

[0065]

[0066] Note: Compared with the model group, *P<0.05, **P<0.01, ***P<0.001.

[0067] Experimental Example 3 Therapeutic effect of Chinese medicine composition on endometriosis in mice

[0068] 1. Experimental Materials

[0069] 1.1 Animals

[0070] Fifty female clean-grade BALB / c mice, 6-8 weeks old, with a sexual cycle of 4-5 days and a body weight of 18-22 g, were purchased from Hangzhou Medical College with production license number: SCXK (Zhejiang) 2019-0002.

[0071] 1.2 Drugs

[0072] The Chinese medicine composition prepared in Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.

[0073] 1.3 Instruments and reagents

[0074] Refrigerator (Haier Company, model: BCD-51OWDEM); electronic balance (Mettler Toledo, model: ME55 / 02); purified water instrument (Millipore, Germany, model: Milli-QPlus); animal weight scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: ACX-SC-DA); multifunctional enzyme microplate reader (Perkin Elmer, model: Inspire); PGE2, PGF2α ELISA detection kit (Nanjing Chuanbo Biotechnology Co., Ltd.)

[0075] 2. Dosage design

[0076] The clinical daily dosage of the Chinese medicine composition is 201.6 g of crude drug / day. According to the body surface area conversion method, the equivalent dose for mice is 201.6 g / 60kg*12.3=41.32 g of crude drug / kg. This dose is set as the medium-dose group, the low-dose group is 20.66 g of crude drug / kg, and the high-dose group is 82.64 g of crude drug / kg.

[0077] 3. Experimental Methods

[0078] Fifty BALB / c female mice were randomly divided into a normal group, a model group, a high-dose Chinese medicine group, a medium-dose Chinese medicine group, and a low-dose Chinese medicine group, with 10 mice in each group. All mice were intragastrically administered with 0.5 mg / kg of estradiol valerate tablets 2 days before surgery to keep the mice in the same estrus phase during surgery. Except for the normal group, all animals in the endometriosis surgery group were anesthetized with 10% urethane 25 mL kg -1 , ip, fixed on the operating table, abdomen disinfected; open the abdominal cavity, ligated the left uterine ovary and vaginal ends of the mouse, cut them off, cut them longitudinally into 2 pieces (5mm×5mm), and sutured them on the bilateral abdominal walls. 1-3 days after surgery, ip, penicillin 1.7 million U·kg -1 After surgery, 0.05 mL of estradiol benzoate was injected intramuscularly every week. -1 1 time to promote the growth of ectopic endometrium. The normal group was opened to find the left uterus, and then the abdominal incision was sutured. All mice were injected intramuscularly with gentamicin for 3 consecutive days after surgery to prevent infection. In the second week of the experiment, the animals in the drug group were gavaged once a day -1 The control group and the model group were given 20 mL kg-1 of distilled water for 4 consecutive weeks.

[0079] 4. Detection indicators

[0080] 4.1 Observation of pain response in mice

[0081] One hour after the last administration, 0.2 mL / mouse of each group was intraperitoneally injected with 0.6% acetic acid, and the number of writhing times of the mice within 20 minutes was recorded.

[0082] 4.2 Detection of ectopic endometrial lesion volume in EMS mice

[0083] The abdominal cavity of the mice was opened layer by layer, the morphology of the ectopic lesions was observed, and the volume of the ectopic lesions (length × width × height, unit: mm) was measured and calculated using a vernier caliper. 3 ).

[0084] 4.3 ELISA kit to detect the levels of PGE2 and PGF2α in mouse serum

[0085] After the writhing observation, the rats were anesthetized by intraperitoneal injection of 5% chloral hydrate (6 ml / kg), and blood was collected by decapitation, which was centrifuged at 3000 r / min for 15 min to separate the serum, which was stored at -80°C and tested according to the instructions of the ELISA kit.

[0086] 5. Experimental results

[0087] The results of the writhing times of mice in each group are shown in Table 3. Compared with the model group, the writhing times of the medium and high dose groups of the Chinese medicine composition were significantly reduced (P < 0.05, P < 0.001).

[0088] After modeling, translucent cysts with a diameter of 5-8 mm appeared in the lesion site of the mice, with fluid accumulation and blood vessel formation, indicating that the modeling was successful. The results of the ectopic endometrial volume of mice in each group are shown in Table 4. Compared with the model group, the ectopic endometrial volume of the high-dose Chinese medicine composition group was significantly reduced (P < 0.001).

[0089] The results of serum ELISA test are shown in Table 5. Compared with the normal group, the expression of serum PGE2 and PGF2α in the model group mice was significantly increased (P < 0.01); compared with the model group, the PGE2 level in the low-, medium- and high-dose groups of the Chinese medicine combination was significantly decreased (P < 0.01, P < 0.001); compared with the model group, the PGF2α level in the high-dose group of the Chinese medicine combination was significantly decreased (P < 0.01).

[0090] Table 3 Number of writhing of mice in each group ( n=10)

[0091]

[0092]

[0093] Note: Compared with the model group, *P<0.05, ***P<0.001.

[0094] Table 4 Volume of ectopic endometrium in each group of mice ( n=10)

[0095]

[0096] Note: Compared with the model group, *P<0.05, **P<0.01, ***P<0.001

[0097] Table 5 PGE2 and PGF2α levels in each group of endometriosis mice ( n=10)

[0098]

[0099] Note: Compared with the model group, *P<0.05, **P<0.01, ***P<0.001

[0100] 6. Experimental conclusion

[0101] After administration of the high and medium dose groups of the Chinese medicine composition, the volume of the ectopic endometrium of rats was significantly reduced, and the levels of serum PGE2 and PGF2α were significantly decreased; after administration of the high dose group of the Chinese medicine composition, the number of torsion of mice was significantly reduced, the volume of the ectopic endometrium was significantly reduced, and the secretion of serum PGE2 and PGF2α was significantly reduced, indicating that the Chinese medicine composition has a good therapeutic effect on endometriosis.

[0102] The above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for preventing and treating endometriosis; The Chinese medicine composition comprises the following raw materials in parts by mass, or is made from the following raw materials in parts by mass: 8-15 parts of Gleditsia sinensis thorns, 6-10 parts of Polygonum cuspidatum, 8-12 parts of Taraxacum herba, 8-12 parts of Sargentodoxae, 8-15 parts of Codonopsis pilosula, 8-15 parts of Smilax china, 6-10 parts of Paeonia lactiflora, 8-15 parts of Salvia miltiorrhiza, 6-10 parts of Linderae umbellatae and 8-12 parts of Corydalis yanhusuo.

2. The use according to claim 1, characterized in that: The raw materials in the Chinese medicine composition include: 12 parts of Gleditsia sinensis thorns, 8 parts of Polygonum cuspidatum, 9.6 parts of Taraxacum mongolicum, 9.6 parts of Sargentodoxae, 12 parts of Codonopsis pilosula, 12 parts of Smilax china, 8 parts of Paeonia lactiflora, 12 parts of Salvia miltiorrhiza, 8 parts of Linderae umbellatae and 9.6 parts of Corydalis yanhusuo.

3. The use according to claim 1, characterized in that: The raw materials in the Chinese medicine composition include: 8 parts of Gleditsia sinensis, 6 parts of Polygonum cuspidatum, 8 parts of Taraxacum herba, 8 parts of Sargentodoxae, 8 parts of Codonopsis pilosula, 8 parts of Smilax china, 6 parts of Paeonia lactiflora, 8 parts of Salvia miltiorrhiza, 6 parts of Linderae umbellatae and 8 parts of Corydalis yanhusuo.

4. The use according to claim 1, characterized in that: The raw materials in the Chinese medicine composition include: 15 parts of Gleditsia sinensis thorns, 10 parts of Polygonum cuspidatum, 12 parts of Taraxacum herba, 12 parts of Sargentodoxae cyrtonema, 15 parts of Codonopsis pilosula, 15 parts of Smilax china, 10 parts of Paeonia lactiflora, 15 parts of Salvia miltiorrhiza, 10 parts of Linderae umbellatae and 12 parts of Corydalis yanhusuo.

5. The use according to any one of claims 1 to 4, characterized in that: The preparation method of the Chinese medicine composition comprises the following steps: Add 6 to 10 times the amount of 60% to 80% ethanol to Corydalis yanhusuo and Polygonum cuspidatum, reflux and extract 1 to 3 times, each time for 0.5 to 2.5 hours, filter, combine the filtrate, and obtain the alcohol extract; Add 10-15 times the amount of water to Gleditsia sinensis, dandelion, Sarsaparilla dahurica, Codonopsis pilosula, Smilax china, Paeonia lactiflora, Salvia miltiorrhiza, and Linderae striata, and boil for 1-4 times, each time for 1-3 hours, filter, combine the filtrate, concentrate under reduced pressure, add ethanol until the alcohol content reaches 60%, let stand for 24-36 hours, and collect the alcohol precipitation supernatant; The alcohol precipitation supernatant and the alcohol extract are combined, concentrated under reduced pressure to obtain an extract, 1-3 times the weight of water of the extract is added to mix well, and allowed to stand for 24-36 hours; the supernatant is taken, dried, and crushed.

6. The use according to any one of claims 1 to 5, characterized in that: The prevention and treatment include: reducing the volume of ectopic endometrium, reducing the level of prostaglandins and / or reducing the number of painful twisting movements.

7. The use according to claim 6, characterized in that: The prostaglandins are prostaglandins in serum, and the prostaglandins include PGE2 and / or PGF2α.

8. The use according to any one of claims 1 to 7, characterized in that: The effective dosage of the traditional Chinese medicine composition is 201.6 g to 403.2 g of crude drug per day.

9. A drug for preventing and treating endometriosis, characterized in that: The invention comprises the following raw materials in parts by weight, or is made from the following raw materials in parts by weight: 8-15 parts of Gleditsia sinensis spines, 6-10 parts of Polygonum cuspidatum, 8-12 parts of Taraxacum herba, 8-12 parts of Sargentodoxae, 8-15 parts of Codonopsis pilosula, 8-15 parts of Smilax china, 6-10 parts of Paeonia lactiflora, 8-15 parts of Salvia miltiorrhiza, 6-10 parts of Linderae umbellatae, and 8-12 parts of Corydalis yanhusuo.

10. The drug according to 9, characterized in that The dosage form of the drug includes granules, capsules, pills, tablets or suppositories.

Images